Mostrar el registro sencillo del ítem
Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal-Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab
dc.contributor.author | Ortiz-Morales, M. José | |
dc.contributor.author | Toledano-Fonseca, Marta | |
dc.contributor.author | Mena-Osuna, Rafael | |
dc.contributor.author | Cano, M. Teresa | |
dc.contributor.author | Gómez-España, M. Auxiliadora | |
dc.contributor.author | Haba-Rodríguez, Juan R. de la | |
dc.contributor.author | Rodríguez-Ariza, Antonio | |
dc.contributor.author | Aranda Aguilar, Enrique | |
dc.date.accessioned | 2022-06-22T06:55:08Z | |
dc.date.available | 2022-06-22T06:55:08Z | |
dc.date.issued | 2022 | |
dc.identifier.uri | http://hdl.handle.net/10396/23253 | |
dc.description.abstract | The identification of factors that respond to anti-angiogenic therapy would represent a significant advance in the therapeutic management of metastatic-colorectal-cancer (mCRC) patients. We previously reported the relevance of VEGF-A and some components of the renin–angiotensin-aldosterone system (RAAS) in the response to anti-angiogenic therapy in cancer patients. Therefore, this prospective study aims to evaluate the prognostic value of basal plasma levels of VEGF-A and angiotensin-converting enzyme (ACE) in 73 mCRC patients who were to receive bevacizumab-based therapies as a first-line treatment. We found that high basal VEGF-A plasma levels were significantly associated with worse overall survival (OS) and progression-free survival (FPS). On the other hand, low ACE levels were significantly associated with poor OS. Importantly, a simple scoring system combining the basal plasma levels of VEGF-A and ACE efficiently stratified mCRC patients, according to OS, into high-risk or low-risk groups, prior to their treatment with bevacizumab. In conclusion, our study supports that VEGF-A and ACE may be potential biomarkers for selecting those mCRC patients who will most benefit from receiving chemotherapy plus bevacizumab treatment in first-line therapy. Additionally, our data reinforce the notion of a close association between the RAAS and the anti-angiogenic response in cancer. | es_ES |
dc.format.mimetype | application/pdf | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | https://creativecommons.org/licenses/by/4.0/ | es_ES |
dc.source | Cancers 14(13), 3054 (2022) | es_ES |
dc.subject | VEGF-A | es_ES |
dc.subject | Angiotensin-converting enzyme | es_ES |
dc.subject | Colorectal cancer | es_ES |
dc.subject | Anti-angiogenic drug | es_ES |
dc.subject | Bevacizumab | es_ES |
dc.subject | Prognosis | es_ES |
dc.subject | Biomarker | es_ES |
dc.title | Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal-Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/cancers14133054 | es_ES |
dc.relation.projectID | Instituto de Salud Carlos III. PI16/01271 | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |